These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8834418)

  • 1. Prediction of haloperidol steady-state levels in plasma after a single test dose.
    Javaid JI; Janicak PG; Sharma RP; Leach AM; Davis JM; Wang Z
    J Clin Psychopharmacol; 1996 Feb; 16(1):45-50. PubMed ID: 8834418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state plasma level prediction for haloperidol from a single test dose.
    Javaid JI; Janicak PG; Hedeker D; Sharma RP; Davis JM
    Psychopharmacol Bull; 1991; 27(1):83-8. PubMed ID: 1862210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
    Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders.
    Janicak PG; Javaid JI; Sharma RP; Leach A; Dowd S; Davis JM
    Acta Psychiatr Scand; 1997 Apr; 95(4):343-50. PubMed ID: 9150830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose treatment with haloperidol: the effect of dose reduction.
    Volavka J; Cooper TB; Czobor P; Lindenmayer JP; Citrome LL; Mohr P; Bark N
    J Clin Psychopharmacol; 2000 Apr; 20(2):252-6. PubMed ID: 10770466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
    Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
    Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol blood levels and clinical effects.
    Volavka J; Cooper T; Czobor P; Bitter I; Meisner M; Laska E; Gastanaga P; Krakowski M; Chou JC; Crowner M
    Arch Gen Psychiatry; 1992 May; 49(5):354-61. PubMed ID: 1586270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
    Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
    J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
    Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Otani K; Kaneko S; Inoue Y
    Clin Pharmacol Ther; 1999 Mar; 65(3):291-4. PubMed ID: 10096261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S
    J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Arch Gen Psychiatry; 1995 Oct; 52(10):837-45. PubMed ID: 7575103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haloperidol plasma concentrations in Taiwanese psychiatric patients.
    Lane HY; Lin HN; Hwu HG; Jann M; Hu WH; Chang WH
    J Formos Med Assoc; 1995 Nov; 94(11):671-8. PubMed ID: 8527974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
    Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Ono S; Kaneko S; Otani K; Inoue Y
    Ther Drug Monit; 2000 Jun; 22(3):245-9. PubMed ID: 10850389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.